Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

Abstract Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent monotherapy. However, little is known about the performa...

Full description

Bibliographic Details
Main Authors: Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri R. Maher
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:eJHaem
Subjects:
acute leukemia
AML
BCL2
chemotherapy
clinical research
malignant hematology
Online Access:https://doi.org/10.1002/jha2.663

Internet

https://doi.org/10.1002/jha2.663

Similar Items